Recently, NRF2 inhibitors that reduce Cisplatin resistance in head and neck cancer [34] have been reported, and it is known that a decrease in the NRF2 downstream target gene HO1 contributes to the reduction of Cisplatin resistance [35]. The gene discussed is NFE2L2; the disease is head and neck cancer.